CAPR · Capricor Therapeutics, Inc.
AI read · Neutral
The AI's read
Capricor's advisory committee voted that deramcicel was not effective for cardiomyopathy in DMD patients, and management will file a narrow BLA amendment focused on upper-limb indications. Q2 showed a $40.7M loss and non-deramcicel work is paused pending regulatory clarity. The news is fresh and clearly negative for the cardiac label. But the stock has already ripped +65.9% and RSI ~70, so market action is pricing a different outcome or optionality. We lean neutral. The headline is bearish, yet the price action and possible PDUFA extension via an amendment create asymmetric near-term dynamics, so wait for clearer regulatory signals before picking a side.